Oncview

OncView™ features trusted experts who actively address the latest data, practice advice, products, and devices in cancer care. Expert, multidisciplinary oncology providers can engage with these educational offerings to learn about the science driving treatment options.

Biomarker Testing and Treatment Strategies in HER2-Overexpressing NSCLC

Biomarker Testing and Treatment Strategies in HER2-Overexpressing NSCLC

November 4th 2024
A Contemporary CancerNetwork OncView Program

A Contemporary CancerNetwork OncView Program

July 31st 2024
Emerging Therapies in Relapsed/Refractory Multiple Myeloma

Emerging Therapies in Relapsed/Refractory Multiple Myeloma

December 12th 2023
Ghayas C. Issa, MD, an expert on acute myeloid leukemia

Exploring Genetic Targeted Therapies in R/R Acute Myeloid Leukemia (AML)

December 5th 2023
Treatment Strategies for Managing Hepatotoxicity and Brain Metastases in KRAS G12C-Mutated NSCLC

Treatment Strategies for Managing Hepatotoxicity and Brain Metastases in KRAS G12C-Mutated NSCLC

November 20th 2023
Sara M. Tolaney, MD, MPH, an expert on breast cancer

Advancements in the Diagnosis and Treatment of Breast Cancer

September 12th 2023
Targeting CD47 in Higher-Risk Myelodysplastic Syndrome (MDS)

Targeting CD47 in Higher-Risk Myelodysplastic Syndrome (MDS)

June 16th 2023
Treatment Strategies in Patients with MDS, MPN and AML

Treatment Strategies in Patients with MDS, MPN and AML

June 6th 2023
André Goy, MD, an expert on B-cell malignancies

Updates in Treatment and Management of B-Cell Malignancies

April 19th 2023
Expert on endometrial carcinoma

Clinical Perspectives in the Evolving Treatment of Advanced Endometrial Carcinoma: Highlights from SGO 2023

April 6th 2023
Experts on multiple myeloma

Updates in CAR T-Cell Therapy and Bispecific Antibodies for the Treatment of Relapsed/Refractory Multiple Myeloma

March 15th 2023
Experts on breast cancer

TNBC: The Changing Treatment Landscape

February 21st 2023
Joshua Richter, MD, an expert on multiple myeloma

Using Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

January 20th 2023
Experts on CRC

HR+ Breast Cancer: 2022 Year in Review

December 15th 2022
Treatment Options for Early-Stage HER2+ Breast Cancer

Treatment Options for Early-Stage HER2+ Breast Cancer

October 7th 2022
Advances in Multiple Myeloma: Insights on Translating Evidence to Clinical Practice

Advances in Multiple Myeloma: Insights on Translating Evidence to Clinical Practice

May 19th 2022
Treatment Options for Early-Stage HER2+ Breast Cancer

Treatment Options for Early-Stage HER2+ Breast Cancer

May 6th 2022
Advances in Systemic Therapy of Differentiated Thyroid Cancer in Second Line and Beyond

Advances in Systemic Therapy of Differentiated Thyroid Cancer in Second Line and Beyond

March 30th 2022
Metastatic Renal Cell Carcinoma: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management

Metastatic Renal Cell Carcinoma: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management

March 22nd 2022
Advances in Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease (GvHD)

Advances in Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease (GvHD)

March 4th 2022
Treatment Options for Early-Stage HER2-Positive Breast Cancer

Treatment Options for Early-Stage HER2-Positive Breast Cancer

February 15th 2022
thoracic oncologist

EGFR Exon 20 Insertion As A Therapeutic Target in Non-small Cell Lung Cancer

November 18th 2021
Recent Updates in Treatment of Non-Metastatic Castration Resistant Prostate Cancer

Recent Updates in Treatment of Non-Metastatic Castration Resistant Prostate Cancer

November 16th 2021
Immunotherapy Response Monitoring in Lung Cancer

Immunotherapy Response Monitoring in Lung Cancer

October 18th 2021
PARP Inhibitors in Prostate Cancer

PARP Inhibitors in Prostate Cancer

October 15th 2021
Immunotherapy Response Monitoring in Melanoma

Immunotherapy Response Monitoring in Melanoma

October 12th 2021
hematologist

Updates in Therapies of Relapse/Refractory Follicular Lymphoma

September 7th 2021
Updates in Therapies of Relapsed and Refractory Follicular Lymphoma

Updates in Therapies of Relapsed and Refractory Follicular Lymphoma

July 6th 2021
NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy

NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy

June 28th 2021
Management of Relapsed/Refractory Follicular Lymphoma

Management of Relapsed/Refractory Follicular Lymphoma

May 12th 2021
12>